Bouchi et al. investigated the impact of insulin treatment on sarcopenia in patients with type 2 DM and found that the insulin-treated group had a significantly higher annual change in skeletal muscle mass than the non-insulin-treated group [23]. Here, INS is linked to sarcopenia.